CN1633305A - 基于抗胆碱能剂和egfr激酶抑制剂的新颖药物组合物 - Google Patents

基于抗胆碱能剂和egfr激酶抑制剂的新颖药物组合物 Download PDF

Info

Publication number
CN1633305A
CN1633305A CNA038039427A CN03803942A CN1633305A CN 1633305 A CN1633305 A CN 1633305A CN A038039427 A CNA038039427 A CN A038039427A CN 03803942 A CN03803942 A CN 03803942A CN 1633305 A CN1633305 A CN 1633305A
Authority
CN
China
Prior art keywords
amino
quinazoline
oxo
chloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038039427A
Other languages
English (en)
Chinese (zh)
Inventor
伯吉特·琼
米歇尔·佩里特
迈克尔·P·皮珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1633305A publication Critical patent/CN1633305A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA038039427A 2002-02-16 2003-02-12 基于抗胆碱能剂和egfr激酶抑制剂的新颖药物组合物 Pending CN1633305A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10206505.5 2002-02-16
DE10206505A DE10206505A1 (de) 2002-02-16 2002-02-16 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern

Publications (1)

Publication Number Publication Date
CN1633305A true CN1633305A (zh) 2005-06-29

Family

ID=27635037

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038039427A Pending CN1633305A (zh) 2002-02-16 2003-02-12 基于抗胆碱能剂和egfr激酶抑制剂的新颖药物组合物

Country Status (21)

Country Link
EP (1) EP1478398B1 (enExample)
JP (1) JP2005517039A (enExample)
KR (1) KR20040083519A (enExample)
CN (1) CN1633305A (enExample)
AR (1) AR038494A1 (enExample)
AT (1) ATE430581T1 (enExample)
AU (1) AU2003206881B2 (enExample)
BR (1) BR0307703A (enExample)
CA (1) CA2476127C (enExample)
CO (1) CO5611134A2 (enExample)
DE (2) DE10206505A1 (enExample)
ES (1) ES2326968T3 (enExample)
MX (1) MXPA04007813A (enExample)
NZ (1) NZ535166A (enExample)
PE (1) PE20030859A1 (enExample)
PL (1) PL369736A1 (enExample)
RU (1) RU2004127869A (enExample)
TW (1) TW200400036A (enExample)
UY (1) UY27670A1 (enExample)
WO (1) WO2003068264A1 (enExample)
ZA (1) ZA200404787B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304978B (zh) * 2005-11-08 2012-12-26 韩美药品株式会社 作为多元抑制剂的喹唑啉衍生物、药物组合物及用途
CN103347518A (zh) * 2011-02-17 2013-10-09 奇斯药制品公司 含有抗毒蕈碱药物的无推进剂液体制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DE102004001607A1 (de) * 2004-01-09 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern
US20060035893A1 (en) * 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042062A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304978B (zh) * 2005-11-08 2012-12-26 韩美药品株式会社 作为多元抑制剂的喹唑啉衍生物、药物组合物及用途
CN103347518A (zh) * 2011-02-17 2013-10-09 奇斯药制品公司 含有抗毒蕈碱药物的无推进剂液体制剂

Also Published As

Publication number Publication date
DE10206505A1 (de) 2003-08-28
UY27670A1 (es) 2003-09-30
JP2005517039A (ja) 2005-06-09
AU2003206881B2 (en) 2009-02-26
ZA200404787B (en) 2005-08-11
CA2476127C (en) 2011-06-14
EP1478398B1 (de) 2009-05-06
KR20040083519A (ko) 2004-10-02
AU2003206881A1 (en) 2003-09-04
ES2326968T3 (es) 2009-10-22
CA2476127A1 (en) 2003-08-21
RU2004127869A (ru) 2005-08-27
BR0307703A (pt) 2005-01-04
PL369736A1 (en) 2005-05-02
AR038494A1 (es) 2005-01-19
DE50311496D1 (de) 2009-06-18
TW200400036A (en) 2004-01-01
CO5611134A2 (es) 2006-02-28
EP1478398A1 (de) 2004-11-24
PE20030859A1 (es) 2003-11-18
WO2003068264A1 (de) 2003-08-21
NZ535166A (en) 2007-01-26
ATE430581T1 (de) 2009-05-15
MXPA04007813A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
US7776315B2 (en) Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20030158196A1 (en) Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20050239778A1 (en) Novel medicament combinations for the treatment of respiratory diseases
US20100099651A1 (en) Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20050165013A1 (en) Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors
CN1649588A (zh) 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物
US20100310477A1 (en) Pharmaceutical compositions based on anticholingerics and additional active ingredients
ZA200606624B (en) Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
CN1633305A (zh) 基于抗胆碱能剂和egfr激酶抑制剂的新颖药物组合物
US20030203918A1 (en) Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound
CN1237970C (zh) 含提欧川平盐的溶液的可吸入制剂
JP4620730B2 (ja) ベータ作動薬を含む吸入用エアロゾル製剤
US20060239935A1 (en) Compositions for inhalation
AU2003242771B2 (en) Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase
CA2582207A1 (en) Inhalation medicament containing an anticholinesterase drug, salmeterol and a steroid selected from the ciclesonide or mometasone furoate group
HK1077748A (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
HK1081460A (en) Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase
CA2551900A1 (en) Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors
US20050203088A1 (en) Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors
HK1078872A (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
CA2430592C (en) New pharmaceutical compositions based on anticholinergics and dopamine agonists
US20050042176A1 (en) Medicaments for inhalation comprising a novel anticholinergic and a steroid
HK1060569B (en) Inhalative solution formulation containing a tiotropium salt
HK1080736A (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
CA2515534A1 (en) New pharmaceutical compositions based on anticholinergics and tace-inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077748

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077748

Country of ref document: HK